Direct
NAV (16-May-24)
Returns (Since Inception)
Fund Size
₹279 Cr
Expense Ratio
0.68%
ISIN
INF966L01CD0
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
18 Jul 2023
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+37.81%
— (Cat Avg.)
Equity | ₹276.41 Cr | 98.90% |
Others | ₹3.07 Cr | 1.10% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Reliance Industries Ltd | Equity | ₹26.22 Cr | 9.38% |
Aurobindo Pharma Ltd | Equity | ₹25.78 Cr | 9.22% |
Poly Medicure Ltd | Equity | ₹24.46 Cr | 8.75% |
Life Insurance Corporation of India | Equity | ₹23.97 Cr | 8.58% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹22.12 Cr | 7.91% |
Indraprastha Medical Corp Ltd | Equity | ₹17.93 Cr | 6.41% |
Jubilant Pharmova Ltd | Equity | ₹16.86 Cr | 6.03% |
Kovai Medical Center & Hospital Ltd | Equity | ₹16.49 Cr | 5.90% |
Gujarat Themis Biosyn Ltd | Equity | ₹13.34 Cr | 4.77% |
Dishman Carbogen Amics Ltd | Equity | ₹13 Cr | 4.65% |
SMS Pharmaceuticals Ltd | Equity | ₹12.3 Cr | 4.40% |
Sequent Scientific Ltd | Equity | ₹11.98 Cr | 4.29% |
Indoco Remedies Ltd | Equity | ₹10.47 Cr | 3.75% |
Suven Life Sciences Ltd | Equity | ₹9.17 Cr | 3.28% |
Granules India Ltd | Equity | ₹8.89 Cr | 3.18% |
Aarti Pharmalabs Ltd | Equity | ₹8.25 Cr | 2.95% |
AstraZeneca Pharma India Ltd | Equity | ₹6.2 Cr | 2.22% |
Brooks Laboratories Ltd | Equity | ₹5.07 Cr | 1.81% |
91 DTB 02052024 | Bond - Gov't/Treasury | ₹5 Cr | 1.79% |
Kopran Ltd | Equity | ₹3.92 Cr | 1.40% |
Nca-Net Current Assets | Cash | ₹-3.09 Cr | 1.10% |
Treps 02-May-2024 Depo 10 | Cash - Repurchase Agreement | ₹1.15 Cr | 0.41% |
Large Cap Stocks
17.96%
Mid Cap Stocks
17.14%
Small Cap Stocks
63.81%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹226.23 Cr | 80.95% |
Energy | ₹26.22 Cr | 9.38% |
Financial Services | ₹23.97 Cr | 8.58% |
Standard Deviation
This fund
--
Cat. avg.
14.57%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.69
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.16
Higher the better
Since July 2023
Since July 2023
Since July 2023
Since July 2023
ISIN | INF966L01CD0 | Expense Ratio | 0.68% | Exit Load | 1.00% | Fund Size | ₹279 Cr | Age | 18 Jul 2023 | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | S&P BSE Healthcare TR INR |
---|
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Flat 15% tax on realised gains (STCG - short term capital gains)
10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)
Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹13.07 Cr | 53.6% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹694.50 Cr | 56.5% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹694.50 Cr | 54.3% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹36.50 Cr | 52.5% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹161.86 Cr | 48.6% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹161.86 Cr | 45.5% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2236.01 Cr | 51.5% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2236.01 Cr | 49.3% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹639.49 Cr | 53.3% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹16.41 Cr | 51.4% |
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Quant Commodities Fund Direct Growth Very High Risk | 0.8% | 1.0% | ₹342.88 Cr | - |
Quant Momentum Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹1654.55 Cr | - |
Quantum Small Cap Fund Direct Growth Very High Risk | 0.6% | 0.0% | ₹47.23 Cr | - |
Quant Teck Fund Direct Growth Very High Risk | 0.8% | 1.0% | ₹350.04 Cr | - |
360 ONE Quant Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹175.14 Cr | 61.5% |
Quant Value Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹1613.09 Cr | 73.5% |
Nippon India Quant Fund Direct Growth Very High Risk | 0.5% | 0.0% | ₹63.00 Cr | 44.2% |
Quant BFSI Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹513.60 Cr | - |
quant Healthcare Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹279.47 Cr | - |
DSP Quant Fund Direct Growth Very High Risk | 0.6% | 0.0% | ₹1179.23 Cr | 21.1% |
ICICI Prudential Quant Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹76.80 Cr | 35.7% |
Axis Quant Fund Direct Growth Very High Risk | 0.8% | 1.0% | ₹1062.73 Cr | 38.3% |
Quant Quantamental Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹2173.52 Cr | 65.3% |
Tata Quant Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹57.67 Cr | 29.0% |
Quant Focused fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹924.73 Cr | 52.5% |
Quant Large and Mid Cap Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹2535.89 Cr | 65.7% |
Quant Active Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹9790.64 Cr | 52.0% |
Quant Small Cap Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹20164.09 Cr | 65.9% |
Quant Absolute Fund Direct Growth Very High Risk | 0.8% | 1.0% | ₹2024.53 Cr | 38.6% |
Quant Infrastructure Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹3187.60 Cr | 78.3% |
Quant Multi Asset Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹2173.05 Cr | 47.9% |
Quant Flexi Cap Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹5562.88 Cr | 58.1% |
Quant Tax Plan Direct Growth Very High Risk | 0.8% | 0.0% | ₹9360.89 Cr | 59.3% |
Quant Liquid Plan Direct Growth Low to Moderate Risk | 0.3% | 0.0% | ₹2395.82 Cr | 7.2% |
Quant Mid Cap Fund Direct Growth Very High Risk | 0.6% | 0.0% | ₹6920.17 Cr | 74.5% |
Quant Gilt Fund Direct Growth Moderate Risk | 0.5% | 0.0% | ₹83.19 Cr | 6.5% |
Quant Manufacturing Fund Direct Growth Very High Risk | 0.8% | 1.0% | ₹651.73 Cr | - |
Quant Business Cycle Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹1236.83 Cr | - |
Quant ESG Equity Fund Direct Growth Very High Risk | 0.8% | 1.0% | ₹253.71 Cr | 48.3% |
Quant Overnight Fund Direct Growth Low Risk | 0.2% | 0.0% | ₹226.10 Cr | 7.3% |
Quant Large Cap Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹997.49 Cr | 52.0% |
Quant Dynamic Asset Allocation Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹1046.84 Cr | 59.0% |
Your principal amount will be at Very High Risk